Enablex, Emselex (darifenacin hydrobromide) is a small molecule pharmaceutical. Darifenacin hydrobromide was first approved as Enablex on 2004-10-22. It is used to treat overactive urinary bladder and urge urinary incontinence in the USA. It has been approved in Europe to treat overactive urinary bladder and urge urinary incontinence. It is known to target muscarinic acetylcholine receptor M1 and muscarinic acetylcholine receptor M3.
|Common Name||Darifenacin hydrobromide|
|Indication||overactive urinary bladder, urge urinary incontinence|
|Drug Class||Muscarinic receptor antagonists|